Clinical and biological characteristics of the French COBRA cohort of adult subjects with asthma
The COhort of BRonchial obstruction and Asthma (COBRA) is a longitudinal cohort that involves 12 French academic institutions. DNA, serum samples and clinical data are collected at entry and every 6 months thereafter.Of 1080 patients with asthma recruited between 2007 and 2015, 401 had mild/moderate...
Gespeichert in:
Veröffentlicht in: | The European respiratory journal 2017-08, Vol.50 (2), p.1700019-1700019 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1700019 |
---|---|
container_issue | 2 |
container_start_page | 1700019 |
container_title | The European respiratory journal |
container_volume | 50 |
creator | Pretolani, Marina Soussan, David Poirier, Isabelle Thabut, Gabriel Aubier, Michel |
description | The COhort of BRonchial obstruction and Asthma (COBRA) is a longitudinal cohort that involves 12 French academic institutions. DNA, serum samples and clinical data are collected at entry and every 6 months thereafter.Of 1080 patients with asthma recruited between 2007 and 2015, 401 had mild/moderate and 613 had severe asthma. In cross-sectional analyses, compared with patients with milder disease, patients with severe asthma had more symptoms, exacerbations, hospitalisations and visits to the emergency department during the preceding 12 months, higher numbers of blood eosinophils, and more comorbidities. More than 60% of patients with severe asthma were therapy-uncontrolled at entry, and 152 of them were being treated with omalizumab. In addition, patients with asthma who had the highest eosinophilia levels (>300/mm
) had shorter asthma duration, lower lung function, and higher rates of severe exacerbations and unacceptable asthma control than patients with lower eosinophil counts.Longitudinal analyses performed in 427 patients with asthma with at least three differential blood cell counts demonstrated that both eosinophil numbers and eosinophil increase over time were associated with the number of exacerbations occurring until the next visit and with Juniper score.Studies with the COBRA cohort will help to improve knowledge concerning the risk and biological factors associated with asthma severity and to better understand their influence on the disease trajectory. |
doi_str_mv | 10.1183/13993003.00019-2017 |
format | Article |
fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_01755575v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1932840888</sourcerecordid><originalsourceid>FETCH-LOGICAL-c412t-203497f278059b167ae77f50af724cfd60ee64e5ce7acb1d10219a3071a6f9a53</originalsourceid><addsrcrecordid>eNpdkUtPxCAUhYnR6Dj6C0wMiRtdVKG0pSzHia9kkkmMrvGWUsukUxSoxn8vdUYXrgiH7z44B6ETSi4pLdkVZUIwQtglIYSKJCWU76DJqCajvIsmRBCWUMGKA3To_SpiRcboPjpIy5KVghcT9DLvTG8UdBj6GlfGdvb156pacKCCdsYHozy2DQ6txrdO96rF8-X14wwr21oXxieohy5gP1QrrYLHnya0GHxo13CE9hrovD7enlP0fHvzNL9PFsu7h_lskaiMpiFuzzLBm5SXJBcVLThozpucQMPTTDV1QbQuMp0rzUFVtKYkpQIY4RSKRkDOpuhi07eFTr45swb3JS0YeT9byFGL9uR5zvMPGtnzDfvm7PugfZBr45XuOui1HbyMlqVlRsro0hSd_UNXdnB9_EmkSiZGJ8fhbEMpZ713uvnbgBI5hiV_w5I_YckxrFh1uu09VGtd_9X8psO-AVwTjOY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1983928835</pqid></control><display><type>article</type><title>Clinical and biological characteristics of the French COBRA cohort of adult subjects with asthma</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Pretolani, Marina ; Soussan, David ; Poirier, Isabelle ; Thabut, Gabriel ; Aubier, Michel</creator><creatorcontrib>Pretolani, Marina ; Soussan, David ; Poirier, Isabelle ; Thabut, Gabriel ; Aubier, Michel ; COBRA cohort Study Group ; COBRA Study Group</creatorcontrib><description>The COhort of BRonchial obstruction and Asthma (COBRA) is a longitudinal cohort that involves 12 French academic institutions. DNA, serum samples and clinical data are collected at entry and every 6 months thereafter.Of 1080 patients with asthma recruited between 2007 and 2015, 401 had mild/moderate and 613 had severe asthma. In cross-sectional analyses, compared with patients with milder disease, patients with severe asthma had more symptoms, exacerbations, hospitalisations and visits to the emergency department during the preceding 12 months, higher numbers of blood eosinophils, and more comorbidities. More than 60% of patients with severe asthma were therapy-uncontrolled at entry, and 152 of them were being treated with omalizumab. In addition, patients with asthma who had the highest eosinophilia levels (>300/mm
) had shorter asthma duration, lower lung function, and higher rates of severe exacerbations and unacceptable asthma control than patients with lower eosinophil counts.Longitudinal analyses performed in 427 patients with asthma with at least three differential blood cell counts demonstrated that both eosinophil numbers and eosinophil increase over time were associated with the number of exacerbations occurring until the next visit and with Juniper score.Studies with the COBRA cohort will help to improve knowledge concerning the risk and biological factors associated with asthma severity and to better understand their influence on the disease trajectory.</description><identifier>ISSN: 0903-1936</identifier><identifier>EISSN: 1399-3003</identifier><identifier>DOI: 10.1183/13993003.00019-2017</identifier><identifier>PMID: 28838976</identifier><language>eng</language><publisher>England: European Respiratory Society Journals Ltd</publisher><subject>Adult ; Anti-Asthmatic Agents - therapeutic use ; Asthma ; Asthma - diagnosis ; Asthma - epidemiology ; Asthma - physiopathology ; Asthma - therapy ; Cohort Studies ; Cross-Sectional Studies ; Deoxyribonucleic acid ; Disease Progression ; DNA ; Emergency Service, Hospital - statistics & numerical data ; Eosinophilia ; Eosinophilia - diagnosis ; Eosinophilia - etiology ; Female ; France - epidemiology ; Hospitalization - statistics & numerical data ; Humans ; Immunoglobulin E ; Leukocytes (eosinophilic) ; Life Sciences ; Longitudinal Studies ; Male ; Middle Aged ; Monoclonal antibodies ; Omalizumab - therapeutic use ; Respiratory function ; Respiratory Function Tests - methods</subject><ispartof>The European respiratory journal, 2017-08, Vol.50 (2), p.1700019-1700019</ispartof><rights>Copyright ©ERS 2017.</rights><rights>Copyright European Respiratory Society Journals Ltd. Aug 2017</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c412t-203497f278059b167ae77f50af724cfd60ee64e5ce7acb1d10219a3071a6f9a53</citedby><cites>FETCH-LOGICAL-c412t-203497f278059b167ae77f50af724cfd60ee64e5ce7acb1d10219a3071a6f9a53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28838976$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-01755575$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Pretolani, Marina</creatorcontrib><creatorcontrib>Soussan, David</creatorcontrib><creatorcontrib>Poirier, Isabelle</creatorcontrib><creatorcontrib>Thabut, Gabriel</creatorcontrib><creatorcontrib>Aubier, Michel</creatorcontrib><creatorcontrib>COBRA cohort Study Group</creatorcontrib><creatorcontrib>COBRA Study Group</creatorcontrib><title>Clinical and biological characteristics of the French COBRA cohort of adult subjects with asthma</title><title>The European respiratory journal</title><addtitle>Eur Respir J</addtitle><description>The COhort of BRonchial obstruction and Asthma (COBRA) is a longitudinal cohort that involves 12 French academic institutions. DNA, serum samples and clinical data are collected at entry and every 6 months thereafter.Of 1080 patients with asthma recruited between 2007 and 2015, 401 had mild/moderate and 613 had severe asthma. In cross-sectional analyses, compared with patients with milder disease, patients with severe asthma had more symptoms, exacerbations, hospitalisations and visits to the emergency department during the preceding 12 months, higher numbers of blood eosinophils, and more comorbidities. More than 60% of patients with severe asthma were therapy-uncontrolled at entry, and 152 of them were being treated with omalizumab. In addition, patients with asthma who had the highest eosinophilia levels (>300/mm
) had shorter asthma duration, lower lung function, and higher rates of severe exacerbations and unacceptable asthma control than patients with lower eosinophil counts.Longitudinal analyses performed in 427 patients with asthma with at least three differential blood cell counts demonstrated that both eosinophil numbers and eosinophil increase over time were associated with the number of exacerbations occurring until the next visit and with Juniper score.Studies with the COBRA cohort will help to improve knowledge concerning the risk and biological factors associated with asthma severity and to better understand their influence on the disease trajectory.</description><subject>Adult</subject><subject>Anti-Asthmatic Agents - therapeutic use</subject><subject>Asthma</subject><subject>Asthma - diagnosis</subject><subject>Asthma - epidemiology</subject><subject>Asthma - physiopathology</subject><subject>Asthma - therapy</subject><subject>Cohort Studies</subject><subject>Cross-Sectional Studies</subject><subject>Deoxyribonucleic acid</subject><subject>Disease Progression</subject><subject>DNA</subject><subject>Emergency Service, Hospital - statistics & numerical data</subject><subject>Eosinophilia</subject><subject>Eosinophilia - diagnosis</subject><subject>Eosinophilia - etiology</subject><subject>Female</subject><subject>France - epidemiology</subject><subject>Hospitalization - statistics & numerical data</subject><subject>Humans</subject><subject>Immunoglobulin E</subject><subject>Leukocytes (eosinophilic)</subject><subject>Life Sciences</subject><subject>Longitudinal Studies</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Monoclonal antibodies</subject><subject>Omalizumab - therapeutic use</subject><subject>Respiratory function</subject><subject>Respiratory Function Tests - methods</subject><issn>0903-1936</issn><issn>1399-3003</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkUtPxCAUhYnR6Dj6C0wMiRtdVKG0pSzHia9kkkmMrvGWUsukUxSoxn8vdUYXrgiH7z44B6ETSi4pLdkVZUIwQtglIYSKJCWU76DJqCajvIsmRBCWUMGKA3To_SpiRcboPjpIy5KVghcT9DLvTG8UdBj6GlfGdvb156pacKCCdsYHozy2DQ6txrdO96rF8-X14wwr21oXxieohy5gP1QrrYLHnya0GHxo13CE9hrovD7enlP0fHvzNL9PFsu7h_lskaiMpiFuzzLBm5SXJBcVLThozpucQMPTTDV1QbQuMp0rzUFVtKYkpQIY4RSKRkDOpuhi07eFTr45swb3JS0YeT9byFGL9uR5zvMPGtnzDfvm7PugfZBr45XuOui1HbyMlqVlRsro0hSd_UNXdnB9_EmkSiZGJ8fhbEMpZ713uvnbgBI5hiV_w5I_YckxrFh1uu09VGtd_9X8psO-AVwTjOY</recordid><startdate>201708</startdate><enddate>201708</enddate><creator>Pretolani, Marina</creator><creator>Soussan, David</creator><creator>Poirier, Isabelle</creator><creator>Thabut, Gabriel</creator><creator>Aubier, Michel</creator><general>European Respiratory Society Journals Ltd</general><general>European Respiratory Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope></search><sort><creationdate>201708</creationdate><title>Clinical and biological characteristics of the French COBRA cohort of adult subjects with asthma</title><author>Pretolani, Marina ; Soussan, David ; Poirier, Isabelle ; Thabut, Gabriel ; Aubier, Michel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c412t-203497f278059b167ae77f50af724cfd60ee64e5ce7acb1d10219a3071a6f9a53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Anti-Asthmatic Agents - therapeutic use</topic><topic>Asthma</topic><topic>Asthma - diagnosis</topic><topic>Asthma - epidemiology</topic><topic>Asthma - physiopathology</topic><topic>Asthma - therapy</topic><topic>Cohort Studies</topic><topic>Cross-Sectional Studies</topic><topic>Deoxyribonucleic acid</topic><topic>Disease Progression</topic><topic>DNA</topic><topic>Emergency Service, Hospital - statistics & numerical data</topic><topic>Eosinophilia</topic><topic>Eosinophilia - diagnosis</topic><topic>Eosinophilia - etiology</topic><topic>Female</topic><topic>France - epidemiology</topic><topic>Hospitalization - statistics & numerical data</topic><topic>Humans</topic><topic>Immunoglobulin E</topic><topic>Leukocytes (eosinophilic)</topic><topic>Life Sciences</topic><topic>Longitudinal Studies</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Monoclonal antibodies</topic><topic>Omalizumab - therapeutic use</topic><topic>Respiratory function</topic><topic>Respiratory Function Tests - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pretolani, Marina</creatorcontrib><creatorcontrib>Soussan, David</creatorcontrib><creatorcontrib>Poirier, Isabelle</creatorcontrib><creatorcontrib>Thabut, Gabriel</creatorcontrib><creatorcontrib>Aubier, Michel</creatorcontrib><creatorcontrib>COBRA cohort Study Group</creatorcontrib><creatorcontrib>COBRA Study Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><jtitle>The European respiratory journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pretolani, Marina</au><au>Soussan, David</au><au>Poirier, Isabelle</au><au>Thabut, Gabriel</au><au>Aubier, Michel</au><aucorp>COBRA cohort Study Group</aucorp><aucorp>COBRA Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical and biological characteristics of the French COBRA cohort of adult subjects with asthma</atitle><jtitle>The European respiratory journal</jtitle><addtitle>Eur Respir J</addtitle><date>2017-08</date><risdate>2017</risdate><volume>50</volume><issue>2</issue><spage>1700019</spage><epage>1700019</epage><pages>1700019-1700019</pages><issn>0903-1936</issn><eissn>1399-3003</eissn><abstract>The COhort of BRonchial obstruction and Asthma (COBRA) is a longitudinal cohort that involves 12 French academic institutions. DNA, serum samples and clinical data are collected at entry and every 6 months thereafter.Of 1080 patients with asthma recruited between 2007 and 2015, 401 had mild/moderate and 613 had severe asthma. In cross-sectional analyses, compared with patients with milder disease, patients with severe asthma had more symptoms, exacerbations, hospitalisations and visits to the emergency department during the preceding 12 months, higher numbers of blood eosinophils, and more comorbidities. More than 60% of patients with severe asthma were therapy-uncontrolled at entry, and 152 of them were being treated with omalizumab. In addition, patients with asthma who had the highest eosinophilia levels (>300/mm
) had shorter asthma duration, lower lung function, and higher rates of severe exacerbations and unacceptable asthma control than patients with lower eosinophil counts.Longitudinal analyses performed in 427 patients with asthma with at least three differential blood cell counts demonstrated that both eosinophil numbers and eosinophil increase over time were associated with the number of exacerbations occurring until the next visit and with Juniper score.Studies with the COBRA cohort will help to improve knowledge concerning the risk and biological factors associated with asthma severity and to better understand their influence on the disease trajectory.</abstract><cop>England</cop><pub>European Respiratory Society Journals Ltd</pub><pmid>28838976</pmid><doi>10.1183/13993003.00019-2017</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0903-1936 |
ispartof | The European respiratory journal, 2017-08, Vol.50 (2), p.1700019-1700019 |
issn | 0903-1936 1399-3003 |
language | eng |
recordid | cdi_hal_primary_oai_HAL_hal_01755575v1 |
source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
subjects | Adult Anti-Asthmatic Agents - therapeutic use Asthma Asthma - diagnosis Asthma - epidemiology Asthma - physiopathology Asthma - therapy Cohort Studies Cross-Sectional Studies Deoxyribonucleic acid Disease Progression DNA Emergency Service, Hospital - statistics & numerical data Eosinophilia Eosinophilia - diagnosis Eosinophilia - etiology Female France - epidemiology Hospitalization - statistics & numerical data Humans Immunoglobulin E Leukocytes (eosinophilic) Life Sciences Longitudinal Studies Male Middle Aged Monoclonal antibodies Omalizumab - therapeutic use Respiratory function Respiratory Function Tests - methods |
title | Clinical and biological characteristics of the French COBRA cohort of adult subjects with asthma |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T06%3A08%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20and%20biological%20characteristics%20of%20the%20French%20COBRA%20cohort%20of%20adult%20subjects%20with%20asthma&rft.jtitle=The%20European%20respiratory%20journal&rft.au=Pretolani,%20Marina&rft.aucorp=COBRA%20cohort%20Study%20Group&rft.date=2017-08&rft.volume=50&rft.issue=2&rft.spage=1700019&rft.epage=1700019&rft.pages=1700019-1700019&rft.issn=0903-1936&rft.eissn=1399-3003&rft_id=info:doi/10.1183/13993003.00019-2017&rft_dat=%3Cproquest_hal_p%3E1932840888%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1983928835&rft_id=info:pmid/28838976&rfr_iscdi=true |